Bilateral atypical femoral fractures after long-term alendronate therapy: A case report

Journal of the Medical Association of Thailand

Volumn 93, Issue 5, 2010, Pages 620-624

  Bamrungsong, Tachchai ^a   Pongchaiyakul, Chatlert ^b  

^a Phranakhon Si Ayutthaya Rajabhat University   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Alendronate; Atypical; Bisphosphonates; Femoral fracture

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID;

AGED; ARTICLE; BONE DENSITY; BONE RADIOGRAPHY; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FALLING; FEMALE; FEMUR FRACTURE; FRACTURE HEALING; HIP; HUMAN; LEG PAIN; LONG TERM CARE; LUMBAR SPINE; OPEN REDUCTION; OSTEOSYNTHESIS; PHYSICAL EXAMINATION; POSTMENOPAUSE OSTEOPOROSIS;

AGED; ALENDRONATE; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY CONSERVATION AGENTS; FEMALE; FEMORAL FRACTURES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 77952928692     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-43.
2. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-99.
3. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
4. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
5. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85: 4118-24.
6. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-38.
7. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Metaanalysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 508-16.
8. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16: 468-74.
9. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; CD001155.
10. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-301.
11. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89: 349-53.
12. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22: 346-50.
13. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358: 1304-6.
14. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008; 39: 224-31.
15. Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008; 359: 316-7.
16. Salminen S, Pihlajamäki H, Avikainen V, Kyrö A, Böstman O.Specific features associated with femoral shaft fractures caused by low-energy trauma. J Trauma 1997; 43: 117-22.
17. Sayed-Noor AS, Sjödén GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy - a case report. Acta Orthop 2008; 79: 565-7.
18. Cheung RK, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007; 13: 485-9.
19. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006; 61: 31-3.
20. Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005; 23(Suppl): 36-42.
21. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28: 524-31.
22. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93: 2948-52.